G6PT Inhibition Model Using HL-60 Cells and Induction of ROS Production through PKC/NOX2 Activation: Clinical Condition for Elucidation of Glycogen Storage Disease Type Ib

DOI Web Site Web Site 参考文献10件
  • Satoh Daisuke
    Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University
  • Ohte Mariko
    Educational Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Science, Nagoya City University
  • Maeda Tohru
    Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University College of Pharmacy, Kinjo Gakuin University
  • Nakamura Katsunori
    Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University Educational Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Science, Nagoya City University
  • Matsunaga Tamihide
    Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University Educational Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Science, Nagoya City University

この論文をさがす

抄録

Glycogen storage disease type Ib (GSD-Ib) is caused by mutations in the glucose-6-phosphate transporter (G6PT) gene, which is involved in glycogen metabolism. Patients with GSD-Ib are known to develop neutropenia as a specific symptom, but the causes remain unclear. To elucidate reduced nicotinamide adenine dinucleotide phosphate (NAD(P)H) oxidase (NOX) 2-associated mechanisms in neutrophil cell membranes, we examined the mechanism of reactive oxygen species (ROS) production after differentiation from HL-60 cells, and the collapse of glycogen metabolism because of G6PT deficiency. ROS production and caspase-3 and -9 activation were observed in G6PT inhibitor-treated neutrophils but not in control cells. Suppression of ROS production by NOX2 inhibitors or protein kinase C (PKC) inhibitors combined with G6PT inhibitor was found to be dependent on the concentration of each inhibitor. Furthermore, ROS production, and caspase-3 and -9 activities were dependent on glucose concentrations. These data indicate that reduced ROS production and suppressed apoptosis in the presence of PKC inhibitors may reflect suppression of PKC-induced NOX2 activation. However, under low glucose conditions, ROS production was reduced and apoptosis was suppressed in neutrophils, suggesting that glucose is a substrate for initiating ROS production. In the present study, the investigation of the pathology of GSD-Ib indicated that a high intracellular glucose level leads to an increase in ROS production by PKC induction and NOX2 activation.

収録刊行物

参考文献 (10)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ